에스트로겐 개요 및 선택 가이드

Estradiol (E2) is the core medication in transgender women’s HRT. When selecting a route of administration, safety (specifically the risk of Venous Thromboembolism, or VTE) should be your primary consideration, rather than just convenience or cost.

VTE Risks by Administration Route

Venous Thromboembolism (blood clots) is one of the most severe risks associated with estrogen therapy. The risk varies dramatically depending on how the estrogen enters your body ^[1] .

Route	Relative Risk (RR)	Evidence Level	Note
Transdermal Patch	RR ≈ 0.97	A	No significant risk increase vs. non-users
Transdermal Gel	RR ≈ 0.97	A	Similar to patches, bypasses liver first-pass
Oral (Estradiol Valerate/Hemihydrate)	RR ≈ 1.48	A	Risk increased by ~48%
Sublingual	Limited Data	C	Partially bypasses first-pass, theoretically lower than oral
Injectable (EV/EC/EEn)	Limited Data	C	Bypasses first-pass, but lacks large RCT data on clot risks

Key Takeaway

Transdermal routes (patches and gel) carry a VTE risk that is statistically identical to people not taking HRT (RR ≈ 0.97). Conversely, oral administration increases the risk by roughly 48% (RR ≈ 1.48). If you possess any prior VTE risk factors, a transdermal route should be your absolute first choice ^[1] .

Route Selection Guide

The following framework is built upon current clinical evidence ^{[2] [3]} :

Scenario 1: Existing VTE Risk Factors

Risk Factors include: Age >40, BMI >30, smoking, family history of VTE, history of clotting disorders, or migraines with aura.

• Preferred: Transdermal Patch or Transdermal Gel
• Avoid: Oral Estradiol
• Also Avoid: Combining oral estrogen with Cyproterone Acetate (CPA)

Scenario 2: No VTE Risk Factors

Choose based on accessibility, budget, and personal preference:

• Oral Estradiol (Estrace, Progynova): Generally the most affordable and widely accessible route globally.
• Transdermal Patch (Climara, Estradot): Superior safety profile, but can be expensive or suffer from global supply chain shortages.
• Sublingual: Uses oral pills dissolved under the tongue. Higher bioavailability but creates massive spikes/drops in blood levels.
• Injectables: Causes significant peak/trough fluctuations but is highly effective for monotherapy.

Scenario 3: Monotherapy (Estrogen Without Anti-Androgens)

If you wish to suppress testosterone using solely estradiol without taking a dedicated anti-androgen blocker:

• Preferred: Injectable Estradiol (EV, EC, EEn) – reliably maintains the consistently high E2 levels required.
• Alternative: High-dose transdermal patches (200-400 µg/day) or transdermal gel.
• Reference: A 2025 study by Misakian demonstrated that 82.6% of users on an injectable EV monotherapy regimen achieved T suppression without needing an anti-androgen ^[4] .

Pros & Cons Quick Reference

Route	Pros	Cons	Typical Accessibility
Transdermal Patch	Lowest VTE risk; stable blood levels; change 1-2 times weekly	Skin irritation; can be expensive or frequently out of stock globally	Moderate
Transdermal Gel	Low VTE risk; flexible daily dosing	Absorption varies wildly by skin type; requires drying time	Moderate
Oral (Pills)	Easiest to access; very cheap; simple to take	Higher VTE risk; liver first-pass metabolism wastes a lot of the drug	Very High
Sublingual	Higher bioavailability than oral; partially bypasses liver	Massive spikes and dips in blood levels; requires dosing 2-3 times daily	Very High (Uses oral pills)
Injectable (EV/EEn)	Bypasses liver; highly effective for monotherapy	Requires needles/injection anxiety; intense blood level peaks and troughs	Varies by country (often DIY)

Dosage Overview

Standard dosage ranges across different routes ^{[2] [3]} :

Route	Starting Dose	Maintenance Dose	Typical Max Dose
Transdermal Patch	50-100 µg/day	100-200 µg/day	400 µg/day
Transdermal Gel	1.5 mg/day	3 mg/day	6 mg/day
Oral Estradiol	2 mg/day	4 mg/day	8 mg/day
Sublingual	1-2 mg/day (split 2-3x)	2-4 mg/day (split 2-3x)	6 mg/day
Injectable EV	1-2 mg/week	2-4 mg/week	5 mg/week

Detailed Pages

For deep dives into the pharmacology, usage methods, and specific warnings for each route, click below:

• Transdermal Patches — The safest administration route
• Oral Estradiol — Highly accessible but carries slightly elevated VTE risks
• Sublingual — A compromise offering higher absorption but dramatic fluctuations
• Transdermal Gel — Flexible safety that sits between patches and oral
• Injectable Estradiol — The gold standard for monotherapy